Insights from 2023 EHA® Annual Meeting

 

Insights from 2023 EHA® Annual Meeting
O

EHA® 2023 Insights: "Venetoclax + Obinutuzumab for Previously Untreated CLL - 6-Year Results of the Randomized CLL14 Study"

By Insights from 2023 EHA® Annual Meeting FEATURING Othman Al-Sawaf
By Insights from 2023 EHA® Annual Meeting FEATURING Othman Al-Sawaf
655 views
July 17, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi
Leukemia
10:42
Insights from 2023 EHA® Annual Meeting

Updated Data for Ziftomenib in Adults With NPM1-Mutated R/R AML

Feat. A. Fathi
16:16
Insights from 2023 EHA® Annual Meeting

Experts Discuss Key Updates in CLL From EHA and iCML

Feat. S. O'Brien, C. Coombs
06:28
Insights from 2023 EHA® Annual Meeting

EHA® 2023 Insights: "Venetoclax + Obinutuzumab for Previously U…

Feat. O. Al-Sawaf
07:51
Insights from 2023 EHA® Annual Meeting

EHA® 2023 Insights: "4-Year Follow-Up From the Randomized Phase…

Feat. A. Kater